Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01198158 · ClinicalTrials.gov registry record · Phase 3
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 3
- Development phase
- 77
- Enrollment target
NCT01198158: Clinical Trial Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT01198158 is a Phase 3 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 77 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01198158, a Phase 3 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 77 participants
- Enrollment target
Study Summary
This randomized phase III trial studies giving everolimus together with bevacizumab to see how well it works compared to everolimus alone in treating patients with advanced kidney cancer that progressed after first-line therapy. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can interfere with tumor growth by blocking the ability of tumor cells to grow and spread. Everolimus and bevacizumab may also stop the growth of kidney cancer by blocking blood flow to the tumor. It is not yet known whether giving everolimus together with bevacizumab is better than everolimus alone in treating patients with advanced kidney cancer that has progressed after first-line therapy.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Everolimus
- BIOLOGICAL Bevacizumab
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2010-09-15 |
| Est. Completion | 2017-12-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01198158
The ClinicalTrials.gov registry entry for NCT01198158 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01198158 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01198158 about?
NCT01198158 is a clinical study titled "Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy". This randomized phase III trial studies giving everolimus together with bevacizumab to see how well it works compared to everolimus alone in treating patients with advanced kidney cancer that progressed after first-line therapy. Everolimus may stop the growth of tumor cells by blocking some of the e...
What is the current status of trial NCT01198158?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 77 participants. The study started on 2010-09-15. Estimated completion is 2017-12-16.
What interventions are being tested in trial NCT01198158?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Everolimus (DRUG), Bevacizumab (BIOLOGICAL), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT01198158?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.